HOLO Labs

References

1. American Psychiatric Association: Diagnostic and statistical manual of mental disorders, Fifth Edition. American Psychiatric Association, 2013.

2. Wy TJP, Saadabadi A: Schizoaffective Disorder. StatPearls [Internet] (ed): StatPearls Publishing, Treasure Island, FL; 2023.

3. Substance Abuse and Mental Health Services Administration: Impact of the DSM-IV to DSM-5 Changes on the National Survey on Drug Use and Health. Substance Abuse and Mental Health Services Administration, Rockville, MD; 2016.

4. Nucifora FC Jr, Woznica E, Lee BJ, Cascella N, Sawa A: Treatment resistant schizophrenia: Clinical, biological, and therapeutic perspectives. Neurobiol Dis. 2019, 131:104257. 10.1016/j.nbd.2018.08.016

5. Siskind D, McCartney L, Goldschlager R, Kisely S: Clozapine v. first- and second- generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2016, 209:385-392. 10.1192/bjp.bp.115.177261

6. Keepers GA, Fochtmann LJ, Anzia JM, et al.: The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia. Am J Psychiatry. 2020, 177:868-872. 10.1176/appi.ajp.2020.177901

7. Buchanan RW, Kreyenbuhl J: An argument for antipsychotic polypharmacy. Am J Psychiatry. 2023, 180:334-336. 10.1176/appi.ajp.20230180

8. Ganguly R, Kotzan JA, Miller LS, Kennedy K, Martin BC: Prevalence, trends, and factors associated with antipsychotic polypharmacy among medicaid-eligible schizophrenia patients, 1998-2000. J Clin Psychiatry. 2004, 65:1377-1388. 10.4088/jcp.v65n1013

9. Gallego JA, Bonetti J, Zhang J, Kane JM, Correll CU: Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res. 2012, 138:18-28. 10.1016/j.schres.2012.03.018

10. Tiihonen J, Wahlbeck K, Kiviniemi V: The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2009, 109:10-14. 10.1016/j.schres.2009.01.002

11. Jang Y, Moon J, Kim N, et al.: A new rapid titration protocol for lamotrigine that reduces the risk of skin rash. Epilepsia Open. 2021, 6:394-401. 10.1002/epi4.12495

12. Xiang YQ, Zheng W, Wang SB, et al.: Adjunctive minocycline for schizophrenia: A meta-analysis of randomized controlled trials. Eur Neuropsychopharmacol. 2017, 27:8-18. 10.1016/j.euroneuro.2016.11.012

13. Panizzutti B, Skvarc D, Lin S, et al.: Minocycline as Treatment for Psychiatric and Neurological Conditions: A Systematic Review and Meta-Analysis. Int J Mol Sci. 2023, 24:10.3390/ijms24065250

14. Okuyama Y, Oya K, Matsunaga S, Kishi T, Iwata N: Efficacy and tolerability of topiramate-augmentation therapy for schizophrenia: a systematic review and meta-analysis of randomized controlled trials. Neuropsychiatr Dis Treat. 2016, 12:3221-3236. 10.2147/NDT.S125367

15. Kang SG, Cho SE, Na KS, Pae CU, Cho SJ: Clinical Usefulness of Amisulpride Add-on Therapy in Schizophrenia Patients without Treatment Response to Second-generation Antipsychotics. Clin Psychopharmacol Neurosci. 2021, 19:117-124. 10.9758/cpn.2021.19.1.117

16. Toledo-Romero F, Molina JD, López-Rodríguez E, Amorin-Díaz M, Muñoz Algar MJ, Aparicio-Castro E: Augmentation with amisulpride for schizophrenic patients non- responsive to risperidone monotherapy. Pharmacopsychiatry. 2015, 48:51-57. 10.1055/s-0034-1395524

17. Molina JD, Toledo-Romero F, López-Rodríguez E, Amorin-Díaz M, Lerma-Carrillo I, López-Muñoz F: Augmentation treatment with amisulpride in schizophrenic patients partially responsive to olanzapine. Pharmacopsychiatry. 2011, 44:142-147. 10.1055/s-0031-1279728